Literature DB >> 25599987

Clinical characteristics of children and young adults with co-occurring autism spectrum disorder and epilepsy.

Christelle M El Achkar1, Sarah J Spence2.   

Abstract

The association between autism spectrum disorder (ASD) and epilepsy has been described for decades, and yet we still lack the full understanding of this relationship both clinically and at the pathophysiologic level. This review evaluates the available data in the literature pertaining to the clinical characteristics of patients with autism spectrum disorder who develop epilepsy and, conversely, patients with epilepsy who develop autism spectrum disorder. Many studies demonstrate an increased risk of epilepsy in individuals with ASD, but rates vary widely. This variability is likely secondary to the different study methods employed, including the study population and definitions of the disorders. Established risk factors for an increased risk of epilepsy in patients with ASD include intellectual disability and female gender. There is some evidence of an increased risk of epilepsy associated with other factors such as ASD etiology (syndromic), severity of autistic features, developmental regression, and family history. No one epilepsy syndrome or seizure type has been associated, although focal or localization-related seizures are often reported. The age at seizure onset can vary from infancy to adulthood with some evidence of a bimodal age distribution. The severity and intractability of epilepsy in populations with ASD have not been well studied, and there is very little investigation of the role that epilepsy plays in the autism behavioral phenotype. There is evidence of abnormal EEGs (especially epileptiform abnormalities) in children with ASD even in the absence of clinical seizures, but very little is known about this phenomenon and what it means. The development of autism spectrum disorder in patients with epilepsy is less well studied, but there is evidence that the ASD risk is greater in those with epilepsy than in the general population. One of the risk factors is intellectual disability, and there is some evidence that the presence of a particular seizure type, infantile spasms, may increase risk, but some of the data are conflicting. We believe that one of the reasons that so little is known about this phenomenon is the lack of cross talk between researchers and clinicians alike in the two fields. We conclude that large systematic studies that employ strict ascertainment of samples using standardized definitions of both disorders, validated data collection tools, and appropriate longitudinal follow-up are needed to better shed light on certain clinical aspects of the comorbidity of ASD and epilepsy. Ideally, we could provide the optimal diagnostic and treatment services to these patients in a multidisciplinary setting with both epilepsy and neurobehavioral specialists. This article is part of a Special Issue entitled "Autism and Epilepsy".
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autism; Autism spectrum disorder; Comorbidity; EEG; Epilepsy; Seizure

Mesh:

Year:  2015        PMID: 25599987     DOI: 10.1016/j.yebeh.2014.12.022

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  35 in total

1.  Parent-Reported Developmental Regression in Autism: Epilepsy, IQ, Schizophrenia Spectrum Symptoms, and Special Education.

Authors:  Kenneth D Gadow; Greg Perlman; Rebecca J Weber
Journal:  J Autism Dev Disord       Date:  2017-04

2.  APC conditional knock-out mouse is a model of infantile spasms with elevated neuronal β-catenin levels, neonatal spasms, and chronic seizures.

Authors:  Antonella Pirone; Jonathan Alexander; Lauren A Lau; David Hampton; Andrew Zayachkivsky; Amy Yee; Audrey Yee; Michele H Jacob; Chris G Dulla
Journal:  Neurobiol Dis       Date:  2016-11-13       Impact factor: 5.996

3.  Amino Acid Dysregulation Metabotypes: Potential Biomarkers for Diagnosis and Individualized Treatment for Subtypes of Autism Spectrum Disorder.

Authors:  Alan M Smith; Joseph J King; Paul R West; Michael A Ludwig; Elizabeth L R Donley; Robert E Burrier; David G Amaral
Journal:  Biol Psychiatry       Date:  2018-09-06       Impact factor: 13.382

4.  Brief Report: Factors Associated with Emergency Department Visits for Epilepsy Among Children with Autism Spectrum Disorder.

Authors:  Wanqing Zhang; Grace Baranek; Brian Boyd
Journal:  J Autism Dev Disord       Date:  2018-05

5.  Retention of autism spectrum disorder diagnosis: The role of co-occurring conditions in males and females.

Authors:  Yen-Tzu Wu; Matthew J Maenner; Lisa D Wiggins; Catherine E Rice; Catherine C Bradley; Maya L Lopez; Russell S Kirby; Li-Ching Lee
Journal:  Res Autism Spectr Disord       Date:  2016-05

Review 6.  Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.

Authors:  Peter E Davis; Jurriaan M Peters; Darcy A Krueger; Mustafa Sahin
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 7.  Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.

Authors:  Katherine C Nickels; Michael J Zaccariello; Lorie D Hamiwka; Elaine C Wirrell
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

8.  Bidirectional association between autism spectrum disorder and epilepsy in child and adolescent patients: a population-based cohort study.

Authors:  Chien-Chou Su; Mei Hung Chi; Shin-Hsien Lin; Yen Kuang Yang
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-01-20       Impact factor: 4.785

9.  Perinatal Immune Activation Produces Persistent Sleep Alterations and Epileptiform Activity in Male Mice.

Authors:  Galen Missig; Emery L Mokler; James O Robbins; Abigail J Alexander; Christopher J McDougle; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2017-10-06       Impact factor: 7.853

Review 10.  Endosomal system genetics and autism spectrum disorders: A literature review.

Authors:  Jameson Patak; Yanli Zhang-James; Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2016-04-02       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.